AstraZeneca's Forxiga Gets EU Approval For Chronic Kidney Disease Treatment
09 August 2021 - 4:58PM
Dow Jones News
By Sabela Ojea
AstraZeneca PLC said Monday that its Forxiga drug has been
approved in the European Union for the treatment of chronic kidney
disease in adults with or without type 2 diabates.
The British-Swedish drugmaker said the approval is based on
positive results from the DAPA-CKD phase three trial.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
August 09, 2021 02:53 ET (06:53 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Mar 2024 to May 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From May 2023 to May 2024